Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (4): 679-683    DOI: 10.12892/ejgo4827.2019
Case Report Previous articles | Next articles
Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report
J.J. Noh1, H. Jung2, C.H. Choi1, *()
1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Download:  PDF(2115KB)  ( 323 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

The authors describe a case of a mesonephric adenocarcinoma of the meso-ovarium and meso-salpinx in a 52-year-old woman. The patient underwent total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, followed by adjuvant chemotherapy with paclitaxel and carboplatin for six cycles with three-week intervals in between. The patient remained free of disease for 18 months with good general conditions. They also reviewed the clinical, pathological, and immunohistochemical characteristics of 42 published case reports of mesonephric adenocarcinoma. The most common presentation of the disease was vaginal bleeding, followed by low abdominal pain. Among the 42 cases reviewed, only three patients were given the correct diagnosis preoperatively. A significant portion of them showed positive immunoreactivity for CD10, vimentin, and calretinin. The authors also found that AE1/AE3, CK7, EMA, CD10, and vimentin are typically positive while ER, PR, and CEA are usually negative. Among the cases reviewed, adjuvant chemotherapy was performed in 11 (26.2%) patients while adjuvant radiotherapy was performed in 16 (38.1%) patients. A number of chemotherapeutic regimens have been used but responses to such regimens are still inconclusive. Although further experiences are needed, surgical removal of the mass followed by paclitaxel and carboplatin adjuvant chemotherapy may be considered as a viable option for treatment.

Key words:  Mesonephric adenocarcinoma      Hysterectomy      Chemotherapy      Paclitaxel      Carboplatin     
Published:  10 August 2019     
*Corresponding Author(s):  C.H. CHOI     E-mail:  chelhun.choi@samsung.com

Cite this article: 

J.J. Noh, H. Jung, C.H. Choi. Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report. European Journal of Gynaecological Oncology, 2019, 40(4): 679-683.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4827.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I4/679

[1] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[2] Youngsun Kim, Sungkyoung Moon, Kiyong Na. Metastatic mesonephric adenocarcinoma of unknown origin after hysterectomy: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 828-832.
[3] Yanan Li, Dongge Wang, Xiaodong Li, Wangchao Zhang, Xianghua Huang, Yibin Liu. Appendix invasion of squamous cell carcinoma arising from ovarian mature cystic teratoma and resistant to combination chemotherapy with docetaxel and oxaliplatin: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 841-844.
[4] John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.
[5] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[6] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[7] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[8] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[9] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[10] Terumi Tanigawa, Maki Matoda, Yoichi Aoki, Hidetaka Nomura, Sanshiro Okamoto, Kohei Omatsu, Hiroyuki Kanao, Nobuhiro Takeshima. A case of recurrent smooth muscle tumor of uncertain malignant potential with abdominal dissemination after morcellation[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 648-650.
[11] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[12] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[13] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[14] Mustafa Ayhan Ekici, Ali Can Onal, Caglar Cetin. Likelihood of incidental finding of gynecological cancer in women undergoing hysterectomy for benign indications[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 402-407.
[15] X.F. Xu, Q. Li, A.Y. Dai, H.J. Zhou, J.X. Ling. Neoadjuvant chemotherapy followed by radical surgery for Stage IB2 cervical cancer in pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 489-491.
No Suggested Reading articles found!